What miraculous effects of erlotinib deserve attention and research?

Erlotinib (Erlotinib), as a small molecule tyrosine kinase inhibitor (TKI), occupies an important position in the field of targeted tumor therapy, especially in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer.

For patients with epidermal growth factor receptor (EGFR) gene mutation-positive non-small cell lung cancer, erlotinib can effectively block the EGFR signaling pathway, inhibit the growth and spread of tumor cells, and significantly extend progression-free survival (PFS) and overall survival (OS). Due to its oral administration, strong targeting, and milder side effects than chemotherapy, erlotinib has become the first-choice targeted therapy drug for many patients with advanced lung cancer, and is even recommended for first-line treatment.

In addition, erlotinib is approved in combination with gemcitabine for patients with locally advanced or metastatic pancreatic cancer. Although the overall prognosis of pancreatic cancer is poor, studies have shown that erlotinib combined with chemotherapy can improve the survival rate of patients to a certain extent. In particular, patients with pancreatic cancer with specific expression of some biomarkers are more likely to obtain therapeutic benefits.

In addition to the above two major indications, the potential application of erlotinib in head and neck cancers, biliary tract tumors and other solid tumors has gradually become a research hotspot in recent years. Scientists are exploring the possibility of combining it with immunotherapy and anti-angiogenic drugs in order to further expand the scope of treatment and improve efficacy.

It is worth mentioning that erlotinib resistance is still a clinical challenge, such asResearch on resistance mechanisms such as T790M mutation provides a theoretical basis for the subsequent development of a new generation of TKI drugs. Therefore, erlotinib not only continues to play a role in clinical applications, but its related research results also continue to promote the development of precision tumor treatment.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib